Click on image to view larger version.
Figure 1. 131I scintigrams of the head and thorax, anterior views. (a) 7 days after the first therapeutic dose, several cervical foci of 131I uptake and diffuse trapping in the lungs. (b) 4 days after the third therapeutic dose, persistence of one cervical focus and lung uptake. (c) Scintigram with 0.7 GBq of 131I 37 days after recombinant thyroid stimulating hormone (rTSH) and the third therapeutic dose: disappearance of 131I uptake at T1 and in the lungs, but the salivary glands and mediastinum are clearly radiolabelled. (d) 5 days after the fourth therapeutic dose: re-appearance of the radiotracer in both lungs and persistence of weak uptake in T1 despite surgery.
